期刊文献+

支气管哮喘患者血清白细胞介素35水平变化及意义 被引量:21

Change of Serum Interleukin 35 Concentration in Asthma and Its Significance
下载PDF
导出
摘要 【目的】探讨支气管哮喘患者血清白细胞介素35水平变化及意义。【方法】将45例受试者分为支气管哮喘组(25例)和健康对照组(20例),测定支气管哮喘组患者未控制、部分控制后1周、控制后1周的血清白细胞介素35(IL-35)水平及各项主要肺功能指标[包括第一秒用力呼气容积(FEV1)与预计值的比值、用力肺活量(FVC)与预计值的比值、FEV1与FVC的比值、呼气峰流量(PEF)与预计值的比值],以及未控制阶段的FEV1下降20%的吸入药物累积浓度(PC20-FEV1),测定健康对照组血清IL-35水平,分析哮喘患者与健康人血清IL-35水平的差异及其与哮喘控制水平、气道反应性的相关性。【结果】支气管哮喘组未控制、部分控制以及控制阶段血清IL-35浓度(pg/mL)分别为141±45、260±84、366±94,健康对照组血清IL-35浓度(pg/mL)为396±120,支气管哮喘组未控制、部分控制阶段血清IL-35水平均低于健康对照组(P值均小于0.001),支气管哮喘组控制阶段与健康对照组血清IL-35水平差异无统计学意义(P=0.36)。血清IL-35水平在未控制阶段低于部分控制阶段(95%置信区间为-163.10~-73.65,P<0.001),部分控制阶段低于控制阶段(95%置信区间为-151.41~-61.97,P<0.001)。哮喘患者血清IL-35水平与哮喘控制水平呈正相关,与PC20-FEV1无相关性。【结论】健康人与哮喘患者血清中均存在IL-35表达,血清IL-35水平可能可以作为哮喘控制水平评估的免疫学参考指标。 [ Objective ] To explore changes and significance of serum interleukin-35 concentration in patients with bronchial asthma. [ Method] Forty-five subjects were divided into two groups: bronchial asthma group with 25 patients and control group with 20 healthy subjects. To detect serum IL-35 concentrations of those uncontrolled, partly controlled and controlled after a week in the asthma group and their main pulmonary function indicators (including FEV1/FEV1 predicted value, FVC/FVC predicted value, FEV1/FVC, PEF/PEF predicted value) and PC20-FEV1 during uncontrolled period, and detect the serum IL-35 concentration of control group, and then analyze the difference of serum IL-35 concentration between both groups and the relevance of serum IL-35 concentration with asthma controlled level and airway reactivity. [ Result] Serum IL-35 concentrations (pg/mL) during uncontrolled period, partly controlled period and controlled period were 141 ± 45, 260 ± 84, 366± 94. Serum IL-35 concentration (pg/mL) in control group was 396 ± 120. Serum IL-35 concentrations of asthma group during uncontrolled and partly controlled periods are lower than control group (t were respectively -9.427 and -4.458, P 〈 0.001 ). There exists no significance difference between serum IL-35 concentrations in asthma group during controlled period and control group (P = 0.36). Serum IL-35 concentration during uncontrolled period is lower than that during partly controlled period (95% Confidence Interval: -163.10- -73.65, P 〈 0.001 ), and serum IL-35 concentration during partly controlled period is lower than that during controlled period (95% Confidence Interval: -151.41 - - 61.97, P 〈 0.001 ). IL-35 level of asthma patients shows positive correlation with asthma controlled level and shows no correlation with PC20-FEV1. [ Conclusion ] There expresses IL-35 in serum of asthma patients and healthy persons. Serum IL-35 concentration may be used as index to test asthma controlled level.
作者 张耀源 张孔
出处 《中山大学学报(医学科学版)》 CAS CSCD 北大核心 2012年第3期398-401,共4页 Journal of Sun Yat-Sen University:Medical Sciences
关键词 支气管哮喘 白细胞介素35 FEV1下降20%的吸入药物累积浓度 bronchial asthma interleukin 35 PC20FEV1
  • 相关文献

参考文献3

二级参考文献23

  • 1Stem F J, Podlaski J D, Hulmes Y E et al. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells[ J]. PNAS, 1990; 87 : 6808-6812.
  • 2Wolf S F,Temple P A, Kobayashi M et al. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biological effects on T and natural killer cells[J]. J Immunol, 1991 ; 146: 3074- 3081.
  • 3Scoenhaut D S, Chua A O, Wolitzky A G et al. Cloning and expression of murine IL-12[J]. J Immunol, 1992; 148;3433-3440.
  • 4Oppnmnn B,Lesley R, Blom Bet al. New p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12[J]. Immunity,2000; 13:715-725.
  • 5Devergne O, Hummel M, koeppen H etal. A novel interleukin-12p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes[ J] .J Virol, 1996;70:1143-11153.
  • 6Devergne O, Birkenbach M, Kieff E. Epstein-Barr vires-induced gene 3 and p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin[ J]. PNAS, 1997 ;94:12041-12046.
  • 7Pflanz S, Timans J C, Cheung Jet al. IL-27, a heteredimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4^+ T cells [ J ]. Immunity, 2002; 16: 779-790.
  • 8Niedbala W, Wei X, Cai B et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulation T cells and suppression of Th17 cells [J]. European J lmmunol, 2007;37:3021-3029.
  • 9Collison L W, Workman C J, Kuo T T etal. The inhibitory cytokine IL-35 contributes to regulatory T cell function [ J ]. Nature, 2007; 450: 566-569.
  • 10Weaver C T, Harrington L E, Mangan P R et al.Th17: Effector CD4 T cell lineage with regtllatory T cell ties[J]. Immunity,2006;24:677-688.

共引文献3565

同被引文献234

引证文献21

二级引证文献240

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部